Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 70/100

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

Key Takeaway: Invivyd, Inc. announced it will host a conference call on May 11, 2023, to discuss its financial results for the first quarter of 2023 and highlight recent business developments. The biopharmaceutical company specializes in creating antibody-based therapies for viral diseases, including COVID-19 and influenza. Their innovative technology and strong pipeline suggest a commitment to addressing pressing public health needs. A replay of the call will be accessible on their website shortly after it concludes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is hosting a conference call to discuss its financial results, indicating transparency and engagement with stakeholders.
  • The company is focused on developing antibody-based therapies which could protect vulnerable populations from viral infections.
  • Invivyd has established a robust pipeline of candidates, suggesting a strong future potential in addressing viral threats.

Full Press Release Details

WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 11, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023, and recent business highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available in the investor section of the company’s website approximately two hours after the end of the call. Those who plan on participating are advised to join 15 minutes prior to the start time.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Kate Burdick, Evoke Canale
Chris Brinzey, ICR Westwicke

Frequently Asked Questions

When will Invivyd host their conference call?

Invivyd will host a conference call on May 11, 2023, at 4:30 p.m. ET.

What will be discussed during the conference call?

The call will cover financial results for Q1 2023 and recent business highlights.

How can analysts join the Q&A session?

Analysts can participate in the Q&A by using a specific registration link.

Where can I find the webcast replay?

The webcast replay will be available in the investor section of Invivyd's website.

What is Invivyd's focus in biopharma?

Invivyd focuses on delivering antibody-based therapies for viral infectious diseases.

Last updated: May 4, 2023